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Background
Adverse drug reactions (ADR) appear more frequently
then what is actually reported and registered. The aim
was to establish an intensive monitoring system and to
analyze ADR in hospitalized patients.
Methods
The prospective study covered 200 patients hospitalized in
the Cardiology Center, Clinical Center of Montenegro.
ADR were recorded in the following way: patients were
interviewed on the basis of a symptoms list and any signs
which could point to eventual ADR. Secondly, lab tests
and other available parameters were monitored.
Results
At the time when interviews took place, patients received
on average 8.0 ± 2.6 medicines (2–17). In total, 67 patients
(33%) had 75 ADR. Twenty one ADR (28%) are classified
as serious. Fifty four ADR resulted in the recovery of the
patient (72%), eight had as an outcome prolonged hospita-
lization (11%), another eight were life threatening (11%),
while five ADR (6%) were the cause of the hospitalization.
The most frequent ADR which had as an outcome admis-
sion to hospital were caused by digoxin (40%), prolonged
hospital stay by furosemide (38%), while the most frequent
registered ADR which were life threatening were caused
by streptokinase (50%).
Conclusions
Monitoring ADR in patients using cardiovascular drugs is
a matter of importance since this class of medicines is
usually used by elderly patients with critical conditions
and accompanying diseases. Considering increased use of
cardiovascular drugs and limitations in pre-marketing
trials for drug safety evaluation, post marketing evalua-
tion of adverse drug reactions induced by this class of
medicinal products seems necessary. Additional educa-
tional efforts could affirm the rationalization of the
pharmacotherapy.
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